Somatostatin Analogue Predisposes Enterocytes to Apoptosis

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The somatostatin analogue octreotide impairs intestinal regeneration and the adaptive response to intestinal resection and other stimuli. These effects are mediated in part by inhibition of enterocyte migration and proliferation. The aim of this study was to determine whether octreotide promotes enterocyte apoptosis. Twenty-four New Zealand white rabbits were studied including 18 animals that underwent patch enteroplasty in the distal ileum to stimulate the mucosa and six unoperated controls. The patched animals either received 100 μg or 1000 μg of subcutaneous octreotide daily or served as operated control subjects. Normal ileal mucosa adjacent to the patch was evaluated at 7 days for villus height, crypt depth, crypt cell production rate (CCPR), and in situ end labeling of DNA fragmentation. Mean DNA fragmentation was significantly greater in octreotide-treated animals (P <0.05 Mann-Whitney rank test). Fragmentation scores ranged from 1.0 to 1.5 in controls and 1.1 to 2.65 in treated animals. Staining of enterocytes was quite heterogenous, however, among the villi of individual treated animals. Staining was greater and cells with chromatin condensation were more prevalent near the tip of the villus. Octreotide increased apoptosis at the villus tip, lateral villus, and crypt. The two control groups had similar villus height, crypt depth, and CCPR. The two octreotide-treated groups had similar villus height and CCPR compared to control animals. However, crypt depth was significantly less in the octreotide-treated animals (100 ± 9 μm, and 90 ± 6 μm, 100 μg, and 1000 μg) compared to controls (121 ± 10 μm and 117 ± 10 μm, unoperated and operated; P <0.05). Crypt depth but not villus height correlated with DNA fragmentation. Neither correlated with CCPR. The following conclusions were reached: (1) Octreotide treatment is associated with increased DNA fragmentation in enterocytes; (2) octreotide promotes apoptosis in both villus and crypt compartments; (3) predisposition to apoptosis may play a role in octreotides effects on intestinal regeneration and adaptation; and (4) the role of proliferation and apoptosis in determining the size of the enterocyte compartments remains unclear.

Original languageEnglish (US)
Pages (from-to)167-173
Number of pages7
JournalJournal of Gastrointestinal Surgery
Volume2
Issue number2
DOIs
StatePublished - Jan 1 1998

Fingerprint

Octreotide
Enterocytes
Somatostatin
Apoptosis
DNA Fragmentation
Regeneration
Mucous Membrane
Staining and Labeling
Ileum
Chromatin
Rabbits
Control Groups

ASJC Scopus subject areas

  • Surgery
  • Gastroenterology

Cite this

Somatostatin Analogue Predisposes Enterocytes to Apoptosis. / Thompson, Jon S.

In: Journal of Gastrointestinal Surgery, Vol. 2, No. 2, 01.01.1998, p. 167-173.

Research output: Contribution to journalArticle

@article{70e341e1e57546d6bdb38b14c475ff5a,
title = "Somatostatin Analogue Predisposes Enterocytes to Apoptosis",
abstract = "The somatostatin analogue octreotide impairs intestinal regeneration and the adaptive response to intestinal resection and other stimuli. These effects are mediated in part by inhibition of enterocyte migration and proliferation. The aim of this study was to determine whether octreotide promotes enterocyte apoptosis. Twenty-four New Zealand white rabbits were studied including 18 animals that underwent patch enteroplasty in the distal ileum to stimulate the mucosa and six unoperated controls. The patched animals either received 100 μg or 1000 μg of subcutaneous octreotide daily or served as operated control subjects. Normal ileal mucosa adjacent to the patch was evaluated at 7 days for villus height, crypt depth, crypt cell production rate (CCPR), and in situ end labeling of DNA fragmentation. Mean DNA fragmentation was significantly greater in octreotide-treated animals (P <0.05 Mann-Whitney rank test). Fragmentation scores ranged from 1.0 to 1.5 in controls and 1.1 to 2.65 in treated animals. Staining of enterocytes was quite heterogenous, however, among the villi of individual treated animals. Staining was greater and cells with chromatin condensation were more prevalent near the tip of the villus. Octreotide increased apoptosis at the villus tip, lateral villus, and crypt. The two control groups had similar villus height, crypt depth, and CCPR. The two octreotide-treated groups had similar villus height and CCPR compared to control animals. However, crypt depth was significantly less in the octreotide-treated animals (100 ± 9 μm, and 90 ± 6 μm, 100 μg, and 1000 μg) compared to controls (121 ± 10 μm and 117 ± 10 μm, unoperated and operated; P <0.05). Crypt depth but not villus height correlated with DNA fragmentation. Neither correlated with CCPR. The following conclusions were reached: (1) Octreotide treatment is associated with increased DNA fragmentation in enterocytes; (2) octreotide promotes apoptosis in both villus and crypt compartments; (3) predisposition to apoptosis may play a role in octreotides effects on intestinal regeneration and adaptation; and (4) the role of proliferation and apoptosis in determining the size of the enterocyte compartments remains unclear.",
author = "Thompson, {Jon S}",
year = "1998",
month = "1",
day = "1",
doi = "10.1016/S1091-255X(98)80009-7",
language = "English (US)",
volume = "2",
pages = "167--173",
journal = "Journal of Gastrointestinal Surgery",
issn = "1091-255X",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Somatostatin Analogue Predisposes Enterocytes to Apoptosis

AU - Thompson, Jon S

PY - 1998/1/1

Y1 - 1998/1/1

N2 - The somatostatin analogue octreotide impairs intestinal regeneration and the adaptive response to intestinal resection and other stimuli. These effects are mediated in part by inhibition of enterocyte migration and proliferation. The aim of this study was to determine whether octreotide promotes enterocyte apoptosis. Twenty-four New Zealand white rabbits were studied including 18 animals that underwent patch enteroplasty in the distal ileum to stimulate the mucosa and six unoperated controls. The patched animals either received 100 μg or 1000 μg of subcutaneous octreotide daily or served as operated control subjects. Normal ileal mucosa adjacent to the patch was evaluated at 7 days for villus height, crypt depth, crypt cell production rate (CCPR), and in situ end labeling of DNA fragmentation. Mean DNA fragmentation was significantly greater in octreotide-treated animals (P <0.05 Mann-Whitney rank test). Fragmentation scores ranged from 1.0 to 1.5 in controls and 1.1 to 2.65 in treated animals. Staining of enterocytes was quite heterogenous, however, among the villi of individual treated animals. Staining was greater and cells with chromatin condensation were more prevalent near the tip of the villus. Octreotide increased apoptosis at the villus tip, lateral villus, and crypt. The two control groups had similar villus height, crypt depth, and CCPR. The two octreotide-treated groups had similar villus height and CCPR compared to control animals. However, crypt depth was significantly less in the octreotide-treated animals (100 ± 9 μm, and 90 ± 6 μm, 100 μg, and 1000 μg) compared to controls (121 ± 10 μm and 117 ± 10 μm, unoperated and operated; P <0.05). Crypt depth but not villus height correlated with DNA fragmentation. Neither correlated with CCPR. The following conclusions were reached: (1) Octreotide treatment is associated with increased DNA fragmentation in enterocytes; (2) octreotide promotes apoptosis in both villus and crypt compartments; (3) predisposition to apoptosis may play a role in octreotides effects on intestinal regeneration and adaptation; and (4) the role of proliferation and apoptosis in determining the size of the enterocyte compartments remains unclear.

AB - The somatostatin analogue octreotide impairs intestinal regeneration and the adaptive response to intestinal resection and other stimuli. These effects are mediated in part by inhibition of enterocyte migration and proliferation. The aim of this study was to determine whether octreotide promotes enterocyte apoptosis. Twenty-four New Zealand white rabbits were studied including 18 animals that underwent patch enteroplasty in the distal ileum to stimulate the mucosa and six unoperated controls. The patched animals either received 100 μg or 1000 μg of subcutaneous octreotide daily or served as operated control subjects. Normal ileal mucosa adjacent to the patch was evaluated at 7 days for villus height, crypt depth, crypt cell production rate (CCPR), and in situ end labeling of DNA fragmentation. Mean DNA fragmentation was significantly greater in octreotide-treated animals (P <0.05 Mann-Whitney rank test). Fragmentation scores ranged from 1.0 to 1.5 in controls and 1.1 to 2.65 in treated animals. Staining of enterocytes was quite heterogenous, however, among the villi of individual treated animals. Staining was greater and cells with chromatin condensation were more prevalent near the tip of the villus. Octreotide increased apoptosis at the villus tip, lateral villus, and crypt. The two control groups had similar villus height, crypt depth, and CCPR. The two octreotide-treated groups had similar villus height and CCPR compared to control animals. However, crypt depth was significantly less in the octreotide-treated animals (100 ± 9 μm, and 90 ± 6 μm, 100 μg, and 1000 μg) compared to controls (121 ± 10 μm and 117 ± 10 μm, unoperated and operated; P <0.05). Crypt depth but not villus height correlated with DNA fragmentation. Neither correlated with CCPR. The following conclusions were reached: (1) Octreotide treatment is associated with increased DNA fragmentation in enterocytes; (2) octreotide promotes apoptosis in both villus and crypt compartments; (3) predisposition to apoptosis may play a role in octreotides effects on intestinal regeneration and adaptation; and (4) the role of proliferation and apoptosis in determining the size of the enterocyte compartments remains unclear.

UR - http://www.scopus.com/inward/record.url?scp=0032009744&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032009744&partnerID=8YFLogxK

U2 - 10.1016/S1091-255X(98)80009-7

DO - 10.1016/S1091-255X(98)80009-7

M3 - Article

C2 - 9834414

AN - SCOPUS:0032009744

VL - 2

SP - 167

EP - 173

JO - Journal of Gastrointestinal Surgery

JF - Journal of Gastrointestinal Surgery

SN - 1091-255X

IS - 2

ER -